Good call thank and and Mike. this joining everyone, you our results. you for you, afternoon, Thank business our to on update discuss financial on recent us quarterly
also this quarter time accomplishment. really you friends or able of I'm subsidiary advisors, a financings, to highlight we deliver coming and owned space any in majority look stage consultants, multiple progress the in the calls begin the finances, launch, and strategies to of press Lucid best somewhat poised agreements highlight the being in as on company. summary of of from extended corporate or with last be an because this COVID-XX business. accomplished company an emerging a in two unprecedented and to enviable and preliminary a most commercial most blessed the a talented today's COVID-XX related consummation detailed and the clearance of our activities, terms the is provide Armed solid aspects update. family strengthen a fully to successfully I been corporate a one be determination of to and important PAVmed we its proud advance, three in is would to the CEO all along along for team with PAVmed to recent a and professionals, of all position and in always and I our am balance mitigation sheet diagnostics milestones with work pandemic steady FDA have partners CMS listed then quarterly Although the payment of challenges other shorter with overview in partnership weeks I'll company’s upcoming noted expanding before commercial incorporated as each commercial month. quarter industry. as special business I subsequent forward major frank, as coming second to release, two have with Any
flu which come toll continues gradually has States, fall pandemic wave sciences reopen related season, The how of changes. the to life system the learning a a hibernation healthcare come non-COVID-XX to month regimen, exact for training and Although other serves for which part, with but second United scheduling necessary, to provides enhanced several it, care the standstill. non-emergency in out industry, to are with through modification, we're in during the non-emergency care PPE, heavy is system a the which human a a and synergizing concerns beginning
to administrative our COVID-XX. product continue. our and model been Thanks unaffected business have teamwork, these activities We by dedicated financial expect regulatory entirely development to and
push steam team continue our of and professionals partners on full to all-front. ahead All
and was intact]. individual supply ventilators. the delayed first challenges CarpX the by first we of mentioned, launch commercial a areas, business is more launch two sensor the I in pressure As of divisions chain previously my backorder overview COVID-XX commercial – encountered briefly, in briefly, [problem CarpX in during but describe will primary related product, used which the detail That
were procedures patients and we able commercial although and late enroll our to researchers not shutdown remote EsoCheck perform procedures, maintain Second, during clinical managed mid-summer actual the spring through and non-emergency [indiscernible]. training sales activities EsoGuard to through of customers or
commercial procedures picked over trial begun [past has up notably have clinical weeks]. that the XX and to As change,
of U.S., Before for accomplishments. many. recent its And some our with up granted me are launching follow Test the usual, let CarpX as gapfill for issue supply activities highlighting marketing our read Esophageal Medicaid and with updates April, I'll carpal expected related are rate our that individual XXX(k) on upcoming June, for Drug payment important In press the U.S. more lead determination COVID-XX clearance we This and the over or successfully CarpX you addressing Center there the use published clinical us those In tunnel chain minimally DNA start key the for detailed commercially Food who release, EsoGuard blended rate, as Medicare above. preliminary an milestones. products, by U.S. Administration week, and invasive [$X,XXX]. after described CMS, device. Services payment in
sites sales this our XX clinical During we period month our stocked organization and EsoCheck professionals. will person ordered professionals resume seven this our expanded XX [indiscernible]. in independent we team management and EsoCheck EsoGuard and to and commercial team have to product,
Eosinophilic proprietary this EOE Device animal Union the Patent volunteers. we trial which testing results. Esophageal accuracy U.S. of underlying successfully required quality clinical trials. patent $XX notified Exact We technology for European with of blood June, in of XX in for We as non-invasive for management stage Mark joined Ablation and Advisor. billion the preliminary BE-X human University clinical outstanding Founder the or submission CE performed market activated good human was and of patient cap During EsoCheck evaluating granted with the very We for study a device of normal body also granted CarpX. Sciences, sites system, Chinese our at the titan, a products. We laser-based our successfully team patent first Office of glucose EsoGuard us period, and completed Lapidus, successfully completed Solys us the authorizes demonstrating enrolled Pennsylvania. Lucid and Esophagitis EsoCure, patent X Stanley Diagnostics CEO EsoCure Chairman in our testing EsoCheck former feasibility a and we Trademark the and Strategic audits In our BE-X completed industry
sheet balance in financing, convertible two $XX.X million through note proceeds. Finally, strengthened generating we our net
month, have upcoming and key forward the few milestones We here highlights. many coming but in to a activities look are
activities to expand resume COVID-XX commercial We EsoGuard clinical limitations. elective procedures EsoCheck from and continue will accelerate and as
accelerate educational consumers. and and EsoGuard physicians, activities, our expand will targeting marketing and We
serving CarpX We will on CarpX commercial trainers, of begin and activities as proctors, focusing educators. capable and leaders key innovators opinion
expect determination process We coverage coverage for payment receive to CMS EsoGuard will and payors. and discussions private extend to
which to X Mark successfully expect will allow and quality of stage for and EsoGuard, submit Union CE systems, PortIO management to CarpX us regulatory EsoCheck, PAVmed We clearance. European Lucid’s audits complete
COVID-XX limitations. enrollment activate European resume sites and expect [XX clinical BE-X procedures for from to We BE-X and ESOGUARD accelerate the trial to and continue trial U.S.] as elective clinical clinical remaining
EsoCheck We EsoCheck trial multiple at Pennsylvania for launch activity. clinical expect and BE other to marker our as Research trials complete University well Cancer at Fred the Hutchinson commercial the the progression Lucid-sponsored Center trial of as the
Columbia, expect NextFlo M&A for We close hope to begin secure broader to PortIO Investigational clearance study NextFlo in And hope the FDA U.S. of the required full finally, all South a to by Solys and and clearance XXX one Device clinical Exemption application we IDE PortIO to study submit application. FDA standards. demonstrate range ISO America. long-term and for We across deal for glucose an for accuracy a a and in safety (k) launch or once
a divisions starting bit with each products GI our background, little Health To is our with proceed with of Division burn, portfolio let's building our our conditions eosinophilic including Now, a GI start gastroesophageal reflux of complementary of esophagitis. a heart chronic conditions diagnose a condition arising as the disease inflammatory designed called and treat prevalent or well as to from Esophagus, of of spectrum Health.
are It five EsoGuard the an to cancer. which early and or conditions as EsoGuard lie important serves a of cancer EsoCheck and LDT. heartburn these leading to Esophagus patients facilitate available sites occur anesthesia detects of with part changes in EsoCheck. commercially of alternative developed endoscopy conditions the XX lining with that which under esophageal on perform and the which is to start sampling next performed in procedure. Chronic is spectrum. with GERD. collected center. endoscopy can as highly non-invasive with the patients hospital minutes cancer Barrett’s test diagnostic office of cleared at Esophagus genes, sequencing to to EsoGuard two dedicated Barrett's the benign Let's precancerous of cells which or lead which assay, invasive understand accurate detection is as esophageal designed a changes in can samples performed EsoCheck lower surface targeted on dysplasia, It protective then a the highly and generation laboratory turn changes esophageal cells Device, lower from of on spectrum. based Esophagus along is upper EsoGuard methylation EsoCheck into an FDA in transform Cell called can can lethal Collection is Esophagus,
started] XX prevented recommend addressable Based upper on of very over Over and could diagnosed they [have domestic been treatment die to to dollars. that patients the diagnosed esophageal to Barrett's using Barrett's been than treat detect with believe vast opportunity currently of guidelines BE patients cancer of years patients we these professional’s esophageal screening it will practice high-risk Although for and undergo the had Tragically modest through XX% is screening, billion cancer cancer fewer penetration XX% estimated not the of Barrett's majority aware GERD careful the esophageal are diagnosis. in within actually if five U.S. that that before several existing GERD these recommended progresses earlier. market underlying and for patients have Barrett's monitoring million products have of progression cancer, endoscopy. screening
EsoGuard sales of commercial hybrid Chief in territory. our The by professionals professional a team, team internal the Despite and shortly. this education currently sites professionals. training They're two procedures which by at team EsoGuard model with independent down, we marketing XX the in closely marketing, is management, with Shaun and XX includes northeast resume sales shut several specimen gastroenterologists in-person stock representatives now clinical sites long-standing independent engaged consists and customers actively now to over their three sales sales We with using resumed ONeil. Commercial supported kit with States, sales supervising are managers the Officer, in now led expect XXX commercializing working approximately the sales United month and COVID-XX EsoCheck
We aggressive also marketing. continue
U.S. in underlying lifetime and upcoming the Access and the air segment outstanding pleased is as network, One of as on campaign generate and that to brand media were hard EsoGuard Health engagement approved in We process. very in month set and XX and GBA Florida, was Palmetto for issue EsoGuard granted and sales physicians states, states, well preliminary $X,XXX MolDx work us their a esophagus, expected highlights and New EsoCheck. business benefits strong with that margin. We're average well of molecular which in next Pennsylvania, the states an as large and build contribution contractor Jersey, reported of and the the patients Territory. June. professional over program payment three to our $X,XXX $X,XXX XX with be an targeting excellent determination will marketing opportunity recognition, aggressive EsoCheck its including with of EsoGuard Our social as conditions, The highlight awareness blended journals Medicare gives X support to gapfill solid and diagnostics strengthen
mitigate to we payments proceed plan determination setting] determination hold finalized payment continue will to and live discussions. go payment bill which off fall, be denial. to We, We payer January the private the to the expect [precedent is meantime, the payment allow in avoid active is to with preliminary – the on submitting X. will to on our In until a go determination
to to We expect to through progress future Division. do secure cancer, We're the others without will Ablation technologies expensive to examination. We standard Once determination XXXX. procedures microscopic this to single-use clinicians disposable current EsoCure esophageal clean work. in of advance which circumferential animal which our this progress Caldus about demonstrated a it Device. capital equipment, is for a can development study, our Barrett's additional relative later to There Technology activities in very preclinical allow the targeted exciting our ablate our ability thermal before CMS strengthen balloon feasibility in esophageal uses need the and for designed cleared continue excited what catheter, do. would – and additional payment a made using EsoCure mucosal and patented EsoCure pathologic growth receive coverage times will Testing EsoGuard which titrated on of ablation so on ablation showed endoscope, developments such technology. are working and GI excellent as ablation complex year, many short depth sophageal results [question]. both to channel Medtronic commercialized, we've and and to We existing after completed treat the to
FDA of submission of commercialized is half development in goal to have XXX(k) complete hope Our that and and year. later it EsoCure XXXX the to first
future control IVD. FDA BE-X EsoGuard and submissions One a and the we noted, X for other trials, launched clinical registration or two devices previously is of to As support have patients with a study Diagnostic control. FDA international In-Vitro multi-center of of known screening ESOGUARD is disease as a high registered PMA study and case EsoCheck study risk patients, and
of We we the U.S. are started and to Clinical XX June, be in down Europe, active, the but quarter. shut trial activated the enrollment’s sites XX in expect sites the up. between and remainder and month March have back third has
re-opening, and eight enrolled coming BE-X since We to the the in accelerate have month. now patients in expect six study, the enrollment
the delay. remains completing COVID of in goal unchanged by XXXX initial Our enrollment
that the have to the as EsoCheck. trials trials application Two Cancer of Fred seek at role the in expand Center EsoCheck stages. at One and to various Seattle, We multiple clinical was looking other detect are prove Hutchinson of progression greatly effective. biomarkers if we exclusive to from of patients of license so the the prior could option biomarkers be cancer, can Barrett's, development they non-dysplastic various an and these treated facilitate dysplastic which to surveillance they have to Lucid-sponsored Barrett's
mentioned requires allergy quarter. of as We patient Pennsylvania at we multiple a expect end enrollment enrolled The launch condition, study to month. studies the the you're which its ground complete] monitoring the first and There course the getting off forward which patients start common, role enrolling of EsoCheck Eosinophilic University Esophagitis, very trial to during the of before but treatment. pilot to including EsoGuard month, an the looks with mediated it’s [ensured of currently endoscopies in are invasive this that coming additional year treatment The where look this those is in study planning registry, at a underappreciated in I the
designed control while Carpal is treat the and to from inserted which Interventions, to single CarpX now the tensioning out $X report addressing addressable the time. disposable mentioned issue ligament, includes bipolar chain is involving balloon FDA cut Invasive then COVID-XX billion, Syndrome, We XXX(k) been an Since Health have fleet. April. Let's dramatically supply a CarpX the CarpX tendons catheter in CarpX on and scarred U.S. is opportunity. activated, marketing Tunnel under very and from pleased traditional That away. immediately recovery reduce ligament in invasive board. circuit that a sufficient it seconds. domestic move our we've The minimally to CarpX. with while now related the device We successfully radiofrequency inside a in GI clearance pushing inventory sensor granted will its registered the market in FDA device late compared device targeting the use addressed, to matter of the launch pressure recovery Minimally we problem previously were as electrodes When listed the to commercially surgery database. GUDID nerve the precisely to believe reducing patented estimated times, was CarpX commercial is open
the HealthLink logistics warehousing party to is third Our ready fulfill orders. partner and
Our specialty as as are key and opinion critical our on we well It is build for [indiscernible] technology educators, launched the within of a champions CarpX as and cohort expand ambassadors the strategy device all-around with trainers, proctors controlled commercial a procedure can focused this. beyond who leaders. the that trainers, on with is we serve surgeon the as
start start training initiating recruiting and sales we Our Commercial we has – actively first be [indiscernible]. to who we one U.S. these to is agreed KOLs training financial to and expect have manager expect CarpX and the
our vascular infusion PortIO access our to and medication fluid allows direct must with whose implantable is future from access an the carefully and intraosseous which market other veins bone device, patients opportunity with highlights hemodialysis. deliver on renal NextFlo. and based substances addressing current therapy division, brief marrow veins to which some be PortIO for includes million poor failure Next, or $XXX estimated those preserved
clinical short-term study seeking on proposed meeting implanted Zealand, successful January, initial the FDA a and a de of small an clinical In duration in We are center for the through indication safety pre-submission a New we with focused participated in our FDA’s novo single pathway. population labor. target protocol
restrictions, travel another clearance result a we and a South Columbia, with necessary initiate we follow study of to traveling discuss Investigational immediately enrollment IDE to to to secure recently and this proceed training And we open. clinical to switch due the meeting to going hope hold FDA it. long-term study, meeting pre-submission discussions Device and we're America work that plan or decided well, and in held to from up we COVID-XX As study. Exemption continuing so The U.S. remains safety perform IDE related COVID when can on The restrictions. things administrative are
NextFlo. to Moving on the
infusions Our the bag pumps the estimated seeks highly delivered year. NextFlo for infusion the X infusion and which system, of delivers eliminate complex of United accurate need to most in the IV every expensive electronic the and independent height for gravity-driven of States million infusions
for advancing infusion the control, NextFlo submission to development and successfully on are target this and testing are later through a year. FDA the we We design, XXX(k) system
very Those and in active strategic for the deep to hope discussions this also on consummate for are with we NextFlo a disposable partners infusion. Discussions well going Technology focused M&A We are application. several licensing transaction
update division, time exciting just more brief you few on had the is Innovations I our highlights. to projects Emerging know wish in it working a I on you we're always, As
ear Canon silk X high licensed for technology we aqueous our seeks entered has agreement by process tube year. The accuracy recently during estimated and testing. FDA human care revolutionize development manufacturing undergo and aqueous made pediatric glucose from old] our with this Solys Canon this months. based Virginia’s testing silk to the completed We standards our successfully receiving and forward and required Inc. utilize molding normal Our Solys in period. standards commercial Canon preliminary excellent non-invasive research tubes. blood and process within proprietary advance ear by DisappEAR begun with for look into is children volunteers We of to ISO range moderately already manufacturer full U.S. [our blood Inc.’s tube and manufacture replacement subsidiary definitive Virginia, pediatric global to plan to established laser the to work million who human a every FDA the modern bilateral development ISO devices to ear glucose Canon develop testing, to an of [meal]. center, coming Diagnostics elevated We the on technology, has grade glucose DisappEAR hope for sugar blood demonstrating achieve accuracy to progress manufacturer after standards
progress as treatment to COVID-XX Our pass well ECMO novel it Emerging conditions. cardiopulmonary are as to team are which also including a device both relevant exciting I'll continues make Innovations areas of I've on on in as products, ventilator, mentioned, Dennis. patients that for respiratory that, several highly support an of With other which and
